DE3104282A1 - Synergistisch antimikrobiell wirksames therapeutisches praeparat und ein verfahren zu dessen herstellung - Google Patents
Synergistisch antimikrobiell wirksames therapeutisches praeparat und ein verfahren zu dessen herstellungInfo
- Publication number
- DE3104282A1 DE3104282A1 DE19813104282 DE3104282A DE3104282A1 DE 3104282 A1 DE3104282 A1 DE 3104282A1 DE 19813104282 DE19813104282 DE 19813104282 DE 3104282 A DE3104282 A DE 3104282A DE 3104282 A1 DE3104282 A1 DE 3104282A1
- Authority
- DE
- Germany
- Prior art keywords
- sisomicin
- derivatives
- doxycycline
- primycin
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 35
- 238000000034 method Methods 0.000 title claims abstract description 15
- 230000001225 therapeutic effect Effects 0.000 title claims abstract description 13
- 230000000845 anti-microbial effect Effects 0.000 title claims abstract description 7
- 230000002195 synergetic effect Effects 0.000 title claims abstract description 7
- URWAJWIAIPFPJE-YFMIWBNJSA-N sisomycin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC=C(CN)O2)N)[C@@H](N)C[C@H]1N URWAJWIAIPFPJE-YFMIWBNJSA-N 0.000 claims abstract description 56
- NYWSLZMTZNODJM-MCGDBQAWSA-N 2-[5-[(4e,20e)-35-butyl-19-[(2s,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-10,12,14,16,18,22,26,30,34-nonahydroxy-3,5,21,33-tetramethyl-36-oxo-1-oxacyclohexatriaconta-4,20-dien-2-yl]-4-hydroxyhexyl]guanidine Chemical compound OC1CC(O)CC(O)CC(O)CC(O)CCCC\C(C)=C\C(C)C(C(C)C(O)CCCN=C(N)N)OC(=O)C(CCCC)C(O)C(C)CCC(O)CCCC(O)CCCC(O)\C(C)=C\C1O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 NYWSLZMTZNODJM-MCGDBQAWSA-N 0.000 claims abstract description 52
- 229950010664 primycin Drugs 0.000 claims abstract description 52
- NYWSLZMTZNODJM-SDUQVVOESA-N primycin Natural products CCCC[C@H]1[C@H](O)[C@H](C)CC[C@@H](O)CCC[C@@H](O)CCC[C@@H](O)C(=C[C@H](O[C@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)C[C@H](O)C[C@@H](O)C[C@H](O)C[C@H](O)CCCCC(=C[C@@H](C)[C@@H](OC1=O)[C@H](C)[C@H](O)CCCNC(=N)N)C)C NYWSLZMTZNODJM-SDUQVVOESA-N 0.000 claims abstract description 52
- 229960005456 sisomicin Drugs 0.000 claims abstract description 50
- URWAJWIAIPFPJE-UHFFFAOYSA-N Rickamicin Natural products O1CC(O)(C)C(NC)C(O)C1OC1C(O)C(OC2C(CC=C(CN)O2)N)C(N)CC1N URWAJWIAIPFPJE-UHFFFAOYSA-N 0.000 claims abstract description 47
- 229930192786 Sisomicin Natural products 0.000 claims abstract description 47
- 229960003722 doxycycline Drugs 0.000 claims abstract description 40
- 239000007788 liquid Substances 0.000 claims abstract description 9
- 239000007787 solid Substances 0.000 claims abstract description 8
- 231100000252 nontoxic Toxicity 0.000 claims abstract description 5
- 230000003000 nontoxic effect Effects 0.000 claims abstract description 5
- 239000000654 additive Substances 0.000 claims abstract description 4
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 claims description 43
- 239000004480 active ingredient Substances 0.000 claims description 25
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 13
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 239000002253 acid Substances 0.000 claims description 6
- 239000000969 carrier Substances 0.000 claims description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 4
- PTNZGHXUZDHMIQ-UHFFFAOYSA-N 4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide;hydrochloride Chemical compound Cl.C1=CC=C2C(C)C(C(O)C3C(C(O)=C(C(N)=O)C(=O)C3N(C)C)(O)C3=O)C3=C(O)C2=C1O PTNZGHXUZDHMIQ-UHFFFAOYSA-N 0.000 claims description 3
- 125000002252 acyl group Chemical group 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 3
- 229960001172 doxycycline hyclate Drugs 0.000 claims description 3
- HALQELOKLVRWRI-VDBOFHIQSA-N doxycycline hyclate Chemical compound O.[Cl-].[Cl-].CCO.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H]([NH+](C)C)[C@@H]1[C@H]2O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H]([NH+](C)C)[C@@H]1[C@H]2O HALQELOKLVRWRI-VDBOFHIQSA-N 0.000 claims description 3
- 229960004082 doxycycline hydrochloride Drugs 0.000 claims description 3
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 3
- 239000011707 mineral Substances 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
- 239000003814 drug Substances 0.000 abstract description 4
- 201000010099 disease Diseases 0.000 abstract description 3
- 244000000010 microbial pathogen Species 0.000 abstract description 3
- 239000000047 product Substances 0.000 abstract 5
- 239000013543 active substance Substances 0.000 abstract 2
- XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 abstract 2
- 239000012263 liquid product Substances 0.000 abstract 1
- 239000003708 ampul Substances 0.000 description 22
- 239000000843 powder Substances 0.000 description 16
- 239000000203 mixture Substances 0.000 description 14
- 210000000481 breast Anatomy 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000002674 ointment Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 6
- 241000191967 Staphylococcus aureus Species 0.000 description 6
- 239000000443 aerosol Substances 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 244000052769 pathogen Species 0.000 description 5
- 239000001632 sodium acetate Substances 0.000 description 5
- 235000017281 sodium acetate Nutrition 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 4
- 239000004359 castor oil Substances 0.000 description 4
- 235000019438 castor oil Nutrition 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 208000004396 mastitis Diseases 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- 229920003023 plastic Polymers 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241001138501 Salmonella enterica Species 0.000 description 3
- 230000001476 alcoholic effect Effects 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 2
- 208000003322 Coinfection Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000193985 Streptococcus agalactiae Species 0.000 description 2
- 206010000269 abscess Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 235000020247 cow milk Nutrition 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000003883 ointment base Substances 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 2
- 229940057838 polyethylene glycol 4000 Drugs 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- BWRBVBFLFQKBPT-UHFFFAOYSA-N (2-nitrophenyl)methanol Chemical compound OCC1=CC=CC=C1[N+]([O-])=O BWRBVBFLFQKBPT-UHFFFAOYSA-N 0.000 description 1
- PTNZGHXUZDHMIQ-CVHRZJFOSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide;hydrochloride Chemical compound Cl.C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O PTNZGHXUZDHMIQ-CVHRZJFOSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000193755 Bacillus cereus Species 0.000 description 1
- 238000009631 Broth culture Methods 0.000 description 1
- 108010065152 Coagulase Proteins 0.000 description 1
- 241001600125 Delftia acidovorans Species 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- 241000186779 Listeria monocytogenes Species 0.000 description 1
- BZARQXGRENRAGM-YQALYVIGSA-N OS(O)(=O)=O.CCCCC1C(O)C(C)CCC(O)CCCC(O)CCCC(O)\C(C)=C\C(OC2OC(CO)C(O)C2O)C(O)CC(O)CC(O)CC(O)CC(O)CCCC\C(C)=C\C(C)C(OC1=O)C(C)C(O)CCCN=C(N)N.CCCCC1C(O)C(C)CCC(O)CCCC(O)CCCC(O)\C(C)=C\C(OC2OC(CO)C(O)C2O)C(O)CC(O)CC(O)CC(O)CC(O)CCCC\C(C)=C\C(C)C(OC1=O)C(C)C(O)CCCN=C(N)N Chemical compound OS(O)(=O)=O.CCCCC1C(O)C(C)CCC(O)CCCC(O)CCCC(O)\C(C)=C\C(OC2OC(CO)C(O)C2O)C(O)CC(O)CC(O)CC(O)CC(O)CCCC\C(C)=C\C(C)C(OC1=O)C(C)C(O)CCCN=C(N)N.CCCCC1C(O)C(C)CCC(O)CCCC(O)CCCC(O)\C(C)=C\C(OC2OC(CO)C(O)C2O)C(O)CC(O)CC(O)CC(O)CC(O)CCCC\C(C)=C\C(C)C(OC1=O)C(C)C(O)CCCN=C(N)N BZARQXGRENRAGM-YQALYVIGSA-N 0.000 description 1
- 241000588770 Proteus mirabilis Species 0.000 description 1
- 241000588767 Proteus vulgaris Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000607715 Serratia marcescens Species 0.000 description 1
- 241000607760 Shigella sonnei Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000203640 Thermomonospora Species 0.000 description 1
- 241000607272 Vibrio parahaemolyticus Species 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000003098 cholesteric effect Effects 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- -1 etc. Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 229950011479 hyclate Drugs 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 229940066263 prednisolone 10 mg Drugs 0.000 description 1
- 229940007042 proteus vulgaris Drugs 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229940115939 shigella sonnei Drugs 0.000 description 1
- 229960001435 sisomicin sulfate Drugs 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000011885 synergistic combination Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19813104282 DE3104282A1 (de) | 1981-02-07 | 1981-02-07 | Synergistisch antimikrobiell wirksames therapeutisches praeparat und ein verfahren zu dessen herstellung |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19813104282 DE3104282A1 (de) | 1981-02-07 | 1981-02-07 | Synergistisch antimikrobiell wirksames therapeutisches praeparat und ein verfahren zu dessen herstellung |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE3104282A1 true DE3104282A1 (de) | 1982-10-28 |
| DE3104282C2 DE3104282C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1990-07-26 |
Family
ID=6124267
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19813104282 Granted DE3104282A1 (de) | 1981-02-07 | 1981-02-07 | Synergistisch antimikrobiell wirksames therapeutisches praeparat und ein verfahren zu dessen herstellung |
Country Status (1)
| Country | Link |
|---|---|
| DE (1) | DE3104282A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0224868A3 (en) * | 1985-11-27 | 1987-08-26 | Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. | Primycine-containing colloidal basic gel, process for its preparation and pharmaceutical or pharmaco-cosmetic compositions containing the basic gel |
| EP0351698A1 (en) * | 1988-07-19 | 1990-01-24 | CHINOIN Gyogyszer és Vegyészeti Termékek Gyára RT. | Synergistic pharmaceutical composition with an antimicrobial action and process for preparing same |
| WO1991012008A1 (en) * | 1990-02-15 | 1991-08-22 | Chinoin Gyógyszer És Vegyészeti Termékek Gyára Rt | Eye-drop |
-
1981
- 1981-02-07 DE DE19813104282 patent/DE3104282A1/de active Granted
Non-Patent Citations (1)
| Title |
|---|
| NICHTS ERMITTELT * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0224868A3 (en) * | 1985-11-27 | 1987-08-26 | Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. | Primycine-containing colloidal basic gel, process for its preparation and pharmaceutical or pharmaco-cosmetic compositions containing the basic gel |
| EP0351698A1 (en) * | 1988-07-19 | 1990-01-24 | CHINOIN Gyogyszer és Vegyészeti Termékek Gyára RT. | Synergistic pharmaceutical composition with an antimicrobial action and process for preparing same |
| WO1991012008A1 (en) * | 1990-02-15 | 1991-08-22 | Chinoin Gyógyszer És Vegyészeti Termékek Gyára Rt | Eye-drop |
Also Published As
| Publication number | Publication date |
|---|---|
| DE3104282C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1990-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2455281B2 (de) | Trockenes, stabiles, pulverförmiges Mittel zur Behandlung von Ruhr und Dehydratisierung sowie Tetanie bei Haustieren (Säugetieren) | |
| DE69003906T2 (de) | Triacetin enthaltende, langwirkende injizierbare Zusammensetzungen. | |
| DE3875295T2 (de) | Bakterizide pharmazeutische zusammensetzung. | |
| DE60125212T2 (de) | Verwendung von Aivlosin zur Behandlung und Prevention der Lawsonia-Infektionen in Schweinen. | |
| EP0655249B1 (de) | Moenomycin als Arzneimittel zur Behandlung von Magengeschwüren | |
| DE2263126A1 (de) | Durch einen cyklus mit 5 kohlenstoffatomen substituierte phenolderivate, deren herstellung und verwendung | |
| DE3104282C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| CH620929A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| DE3511307A1 (de) | Synergistisch wirkende kombinationsarzneimittel | |
| DE3153623C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| CH677608A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| US4404189A (en) | Synergistic antimicrobial compositions | |
| EP0194466A2 (de) | Kombination zur antimikrobiellen und antioxidativen Stabilisierung von Externa und Körperpflegemitteln | |
| DE1931466C3 (de) | Kupfer (Il)-komplexe von 6-Niederalkoxy-1-phenazinol- 5,10 - dioxiden | |
| DD141995A5 (de) | Verfahren zur herstellung detoxifizierter zubereitungen von cytostatika | |
| DE3785953T2 (de) | Bakterientötende Gemische. | |
| CH650929A5 (en) | A therapeutic product with synergistic antimicrobial activity and a process for its production | |
| US4501732A (en) | Synergistic antimicrobial compositions | |
| GB2103085A (en) | Antimicrobial compositions containing primycin and doxycycline and/or sisomycin or a derivative thereof | |
| EP0135657B1 (de) | Arzneimittel und/oder Futtermittelkonzentrate mit antibakterieller Wirkung | |
| DE69528922T2 (de) | Herstellung von 2-Bromo-5-(2-bromo-2-nitro-vinyl)-furan und deren Verwendung als Microzide | |
| DE3147311C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| EP0123157B1 (de) | Arzneimittel und/oder Futtermittelkonzentrate mit antibakterieller Wirkung | |
| CA1155765A (en) | Synergistic antimicrobial compositions | |
| DE2650608A1 (de) | Arzneipraeparat zur behandlung von mastitis bei milchvieh |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8110 | Request for examination paragraph 44 | ||
| 8128 | New person/name/address of the agent |
Representative=s name: LOTTERHOS, H., DIPL.-ING. DR.-ING. BARTSCH, E., DI |
|
| D2 | Grant after examination | ||
| 8380 | Miscellaneous part iii |
Free format text: SEITE 3, ZEILE 67: "+ = SEHR SCHWACHER WACHSTUM" UNTER DAS "PLUS-ZEICHEN" IST EIN "MINUSZEICHEN" ZUSETZEN |
|
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |